NCT01678755已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers
AbbVie (prior sponsor, Abbott)20 个研究点 分布在 1 个国家目标入组 157 人开始时间: 2012年8月最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 157
- 试验地点
- 20
- 主要终点
- Cognition: MCCB (MATRICS Consensus Cognitive Battery) change from baseline to week 12
研究概览
简要总结
This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
详细描述
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects with Schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 20 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a current Diagnostic and Statistical Manual of Mental Disorders-, 4th Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview (M.I.N.I.).
- •Is clinically stable while receiving a regimen of one or two allowable antipsychotic medications; lack of hospitalizations in 4 months prior to initial screening visit; taking the same antipsychotic medication(s) for at least 8 weeks prior to baseline visit; core positive symptoms of Positive and Negative Syndrome Scale (PANSS) no worse than moderate in severity throughout screening period of at least 4 weeks.
- •Has been diagnosed with or treated for schizophrenia for at least 2 years prior to initial screening visit.
- •Has had continuity in psychiatric care (e.g., mental health system, clinic or physician) for at least 6 months prior to initial screening visit.
- •Has an identified contact person (e.g., family member, social worker, case worker, or nurse) that can provide support to the subject to ensure compliance with protocol requirements.
排除标准
- •In the Investigator's judgment, has a current or past diagnosis of schizoaffective disorder, bipolar disorder, manic episode, dementia, post traumatic stress disorder, or obsessive-compulsive disorder, or the subject has a current major depressive episode.
- •Has a positive urine drug screen for cocaine, phencyclidine (PCP), opiates (unless duly prescribed), benzodiazepines (unless duly prescribed), marijuana, or amphetamines during the Screening Period.
- •Has a current or past history of seizures, with the exception of a single febrile seizure occurring prior to 6 years of age.
- •Has a clinically significant abnormal electrocardiogram (ECG) at Screening Visit 1 as determined by the Investigator.
- •Has any risk factors for Torsades de Pointes (TdP)
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
ABT-126 Low Dose
Experimental
ABT-126 Low Dose
干预措施: ABT-126 (Drug)
ABT-126 High Dose
Experimental
ABT-126 High Dose
干预措施: ABT-126 (Drug)
结局指标
主要结局
Cognition: MCCB (MATRICS Consensus Cognitive Battery) change from baseline to week 12
时间窗: Change from baseline to week 12
Rater based interview
次要结局
- Functioning: UPSA-2 (University of California San Diego Performance-based Skills Assessment-2)(Measurements from screening period up through week 12)
- Symptom Severity: PANSS (Positive and Negative Syndrome Scale)(Measurements from screening period up through week 12)
- Symptom Severity: NSA-16 (16-item version of the Negative Symptom Assessment Scale)(Measurements from screening period up through week 12)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With SchizophreniaCognitive Deficits in SchizophreniaNCT01077700AbbVie (prior sponsor, Abbott)214
已完成
2 期
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With SchizophreniaCognitive Deficits in SchizophreniaNCT01095562AbbVie (prior sponsor, Abbott)207
已完成
2 期
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaSchizophreniaNCT01655680AbbVie (prior sponsor, Abbott)432
已完成
2 期
Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)Alzheimer DiseaseNCT02361424Pharnext S.C.A.47
终止
2 期
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's DiseaseAlzheimer DiseaseDementia, Alzheimer TypeNCT02322021Eisai Inc.70